Across TCGA pan-cancer cohorts, FITM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FITM2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FITM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FITM2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where FITM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.174	0.948	.024	15	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	14	view →
GBM	DFS	Tertile	All	0.507	0.298	.005	6	view →
PDAC	DFS	Quartile	III,IV	0.496	0.868	.030	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FITM2 tumor-vs-normal RNA expression · all FITM2 data types